On Tuesday, MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) said it completed the current Good Laboratory Practice preclinical safety program for Ketamir-2, a novel oral ketamine analog. The results confirm ...
Source LinkOn Tuesday, MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) said it completed the current Good Laboratory Practice preclinical safety program for Ketamir-2, a novel oral ketamine analog. The results confirm ...
Source Link
Comments